Penumbra (PEN) Aperçu de l'action
Penumbra, Inc. et ses filiales conçoivent, développent, fabriquent et commercialisent des dispositifs médicaux aux États-Unis et dans le monde entier. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 0/6 |
| Croissance future | 2/6 |
| Performances passées | 2/6 |
| Santé financière | 6/6 |
| Dividendes | 0/6 |
Récompenses
Analyse des risques
Aucun risque n'a été détecté pour PEN à partir de nos contrôles de risques.
PEN Community Fair Values
Create NarrativeSee what 12 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Penumbra, Inc. Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | US$327.17 |
| Plus haut sur 52 semaines | US$362.41 |
| Plus bas sur 52 semaines | US$221.26 |
| Bêta | 0.70 |
| Variation sur 1 mois | 2.78% |
| Variation sur 3 mois | 0.19% |
| Variation sur 1 an | 28.13% |
| Variation sur 3 ans | 31.55% |
| Variation sur 5 ans | 23.73% |
| Évolution depuis l'introduction en bourse | 692.18% |
Nouvelles et mises à jour récentes
Mise à jour du récit • Jul 16
PEN: Merger Progress And Stroke Trial Data Will Shape Fair Outlook
Analysts have raised their price target on Penumbra to about $325 from roughly $239, citing updated assumptions for fair value, discount rate, revenue growth, profit margin and future P/E, which collectively support a higher estimated valuation range for the stock. What’s in the News for Penumbra Penumbra shareholders approved the proposed merger with Boston Scientific Corporation at a special meeting on May 6, 2026, including compensation arrangements for named executive officers, according to recent shareholder meeting results.
Mise à jour du récit • Jul 01
PEN: Stroke Device Approvals And Merger Outlook Will Drive Future Upside
Analysts have adjusted their price target for Penumbra to $374 from $355, citing updated assumptions related to discount rates, revenue growth, profit margins, and future P/E expectations. What’s in the News for Penumbra Penumbra received U.S. FDA clearance and European CE Mark approval for its THUNDERBOLT computer assisted vacuum thrombectomy system for acute ischemic stroke, the first CAVT platform approved in the U.S. specifically for stroke care, according to recent news reports.Recent updates
Mise à jour du récit • Jul 16
PEN: Merger Progress And Stroke Trial Data Will Shape Fair Outlook
Analysts have raised their price target on Penumbra to about $325 from roughly $239, citing updated assumptions for fair value, discount rate, revenue growth, profit margin and future P/E, which collectively support a higher estimated valuation range for the stock. What’s in the News for Penumbra Penumbra shareholders approved the proposed merger with Boston Scientific Corporation at a special meeting on May 6, 2026, including compensation arrangements for named executive officers, according to recent shareholder meeting results.Mise à jour du récit • Jul 01
PEN: Stroke Device Approvals And Merger Outlook Will Drive Future Upside
Analysts have adjusted their price target for Penumbra to $374 from $355, citing updated assumptions related to discount rates, revenue growth, profit margins, and future P/E expectations. What’s in the News for Penumbra Penumbra received U.S. FDA clearance and European CE Mark approval for its THUNDERBOLT computer assisted vacuum thrombectomy system for acute ischemic stroke, the first CAVT platform approved in the U.S. specifically for stroke care, according to recent news reports.Article d’analyse • Jun 19
Penumbra (PEN) Stock Could Be 12.7% Undervalued On STORM PE Trial Hopes
Penumbra (PEN) is back in focus after recent trading left the stock around $317.20, prompting investors to reassess its performance over the past month and past 3 months. See our latest analysis for Penumbra. Looking beyond the latest move, Penumbra’s 1 year total shareholder return of 23.42% contrasts with a year to date share price return of 2.51%, while the 3 year total shareholder return has declined 6.7%. This suggests that momentum has cooled after stronger recent gains. If you are...
Mise à jour du récit • Jun 17
PEN: Pulmonary Embolism Trial And Merger Approval Will Support Stronger Outlook
Analysts have maintained their Penumbra price target at approximately $363, noting only minor adjustments to factors such as the discount rate, assumptions about long-term revenue growth and profit margins, and the projected future P/E multiple. What’s in the News for Penumbra Boston Scientific announced plans to acquire Penumbra, with Artisan Partners highlighting the deal as confirmation of its prior investment thesis in Penumbra stock and using the transaction to exit its position.Mise à jour du récit • Jun 03
PEN: Positive Pulmonary Embolism Trial Outcomes Will Support A Stronger Forward Outlook
Analysts have slightly trimmed their price target on Penumbra to $363.36 from $365.79, reflecting updated assumptions around the discount rate, revenue growth, profit margins, and future P/E. What's in the News Penumbra reported 90 day results from the STORM-PE randomized controlled trial, where patients with acute intermediate high risk pulmonary embolism treated with computer assisted vacuum thrombectomy (CAVT) plus anticoagulation showed greater functional improvement than those on anticoagulation alone, including longer six minute walk distances and a higher share reaching NYHA Class I, according to data presented at the Society of Interventional Radiology Annual Scientific Meeting.Mise à jour du récit • Apr 25
PEN: Trial Outcomes And Steady Assumptions Will Shape Balanced Forward Outlook
Analysts have maintained their price target on Penumbra at $365.79, making only minor adjustments to inputs such as discount rate, revenue growth, profit margin and future P/E assumptions to reflect updated views on the company’s risk profile and earnings potential. What's in the News Ninety-day results from the STORM-PE randomized controlled trial showed that patients with acute intermediate high risk pulmonary embolism treated with computer assisted vacuum thrombectomy plus anticoagulation walked longer distances in the six minute walk test, reached higher predicted walk distances, and had a higher share of patients with no physical limitations compared with anticoagulation alone, with broadly comparable safety outcomes through 90 days (Key Developments).Mise à jour du récit • Apr 08
PEN: Merger Terms And Steady Assumptions Will Shape Balanced Forward Outlook
Analysts have raised their price target for Penumbra to $365.79 from $360.13, citing updated assumptions for discount rate, revenue growth, profit margin and future P/E that together support a slightly higher valuation framework. What's in the News Boston Scientific Corporation agreed to acquire Penumbra for US$14.8b under a definitive merger agreement announced on January 14, 2026.Mise à jour du récit • Mar 25
PEN: Merger Agreement And Steady Metrics Will Shape Measured Forward Outlook
Analysts have kept their $360.13 price target for Penumbra broadly unchanged, citing slightly adjusted assumptions for the discount rate, revenue growth, profit margin and future P/E. Taken together, these changes leave their overall valuation view steady for now.Mise à jour du récit • Mar 11
PEN: Proposed Buyout Terms And Revised Assumptions Will Shape Balanced Outlook
Analysts have nudged their price target on Penumbra higher to about $360 from roughly $349, citing updated assumptions that combine slightly lower revenue growth and a modestly lower future P/E with a somewhat higher profit margin outlook and a small adjustment to the discount rate. What's in the News Boston Scientific agreed to acquire Penumbra in a cash and stock deal valued at about US$14.8b, pricing each Penumbra share at US$374.Mise à jour du récit • Feb 24
PEN: Proposed Cash And Stock Buyout Will Define Balanced Risk Reward Profile
Analysts have maintained their fair value estimate for Penumbra at about $348.53, with only a slight adjustment to key model inputs such as the discount rate and future P/E. This reflects updated assumptions rather than a major shift in outlook.Mise à jour du récit • Feb 10
PEN: Proposed Takeover Terms And Steady Outlook Will Shape Risk Reward Balance
Analysts now hold Penumbra's fair value estimate steady at about $348.53 per share, with only slight tweaks to inputs such as the discount rate and future P/E. This reflects a largely unchanged view of the stock's risk and earnings profile.Mise à jour du récit • Jan 27
PEN: Acquisition Proposal And 2025 Guidance Will Shape Future Risk Reward Balance
Analysts have raised their price target on Penumbra by about $11 per share, citing updated assumptions that include slightly higher fair value estimates, a modestly lower discount rate, and small adjustments to revenue growth, profit margin, and future P/E expectations. What's in the News Boston Scientific entered into a definitive agreement to acquire Penumbra for $14.8b, valuing each Penumbra share at $374, with stockholders able to elect cash or Boston Scientific stock, subject to proration and regulatory and shareholder approvals (M&A Transaction Announcement).Mise à jour du récit • Jan 11
PEN: Trial Results And 2025 Guidance Will Shape Future Risk Reward Balance
Analysts have increased their price target on Penumbra by about $10 to reflect updated fair value assumptions, a slightly lower discount rate, modestly higher revenue growth expectations, a small adjustment to profit margin forecasts, and a higher future P/E multiple. What's in the News Penumbra updated its earnings guidance for 2025 and now expects total revenue in a range of US$1.375b to US$1.380b, based on 2024 revenue of US$1.195b, while maintaining its full year 2025 gross margin and operating margin guidance (Key Developments).Article d’analyse • Jan 11
Do Penumbra's (NYSE:PEN) Earnings Warrant Your Attention?
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Mise à jour du récit • Dec 27
PEN: Trial Data And 2025 Guidance Will Shape Future Risk Reward Balance
Analysts have modestly raised their price target on Penumbra, increasing the estimated fair value by about $18 to roughly $328 per share. This reflects slightly stronger expectations for long term revenue growth and sustainable earnings multiples, despite only marginal tweaks to discount rate and margin assumptions.Seeking Alpha • Dec 15
Penumbra: Well-Placed For Above-Average Growth, But Mind The Volatility
Summary Penumbra offers compelling growth in mechanical thrombectomy, with strong recent results and expanding addressable markets in pulmonary embolism and neurovascular. PEN’s STORM-PE and CLOSABLE studies and upcoming Thunderbolt launch position the company for accelerated adoption and revenue growth in 2026 and beyond. Valuation remains challenging, with shares trading at high multiples, but robust growth and potential M&A interest justify a more flexible stance. I see around 10% upside at current levels, with beat-and-raise potential and long-term EBITDA margin expansion into the mid-20% range. Read the full article on Seeking AlphaMise à jour du récit • Dec 13
PEN: Clinical Trial Outcomes And 2025 Guidance Will Shape Balanced Outlook
Analysts have nudged their price target on Penumbra slightly higher, to approximately $310 per share from about $307, citing a modestly lower discount rate and a higher long term earnings multiple that more than offset a small trim to projected profit margins. What's in the News Penumbra raised its 2025 total revenue guidance to a range of $1.375 billion to $1.380 billion, implying 15% to 16% growth over 2024, while reiterating full year gross and operating margin targets (company guidance).Article d’analyse • Nov 28
Penumbra, Inc. (NYSE:PEN) Looks Just Right With A 27% Price Jump
Penumbra, Inc. ( NYSE:PEN ) shares have had a really impressive month, gaining 27% after a shaky period beforehand...Mise à jour du récit • Nov 21
PEN: Upcoming Clinical Results And Balanced Outlook Will Shape 2025 Performance
Analysts have modestly raised their price target for Penumbra from $306.74 to $306.79, citing incremental improvements in projected revenue growth and a slight decrease in the discount rate as key factors supporting the adjustment. What's in the News Penumbra updated its 2025 guidance, increasing expected total revenue to $1.375 to $1.38 billion, reflecting 15% to 16% growth over 2024, and maintained its gross and operating margin outlook for the year (Corporate Guidance).Mise à jour du récit • Nov 07
PEN: Latest Clinical Trial Results Will Drive Global Expansion Momentum
Analysts have raised their price target for Penumbra from $303.33 to $306.74, citing modest improvements in profit margin and revenue growth forecasts. What's in the News Penumbra raised its 2025 revenue guidance to a range of $1.375 billion to $1.38 billion, representing 15% to 16% growth over 2024 figures, and reaffirmed its gross and operating margin guidance (Key Developments).Mise à jour du récit • Sep 08
STORM-PE Trial And New Therapies Will Expand Global Reach
The reduction in Penumbra’s Analyst Price Target reflects a combination of weakening net profit margins and a higher future P/E multiple, with fair value revised down from $310.24 to $303.33. What's in the News Company completed repurchase of 517,763 shares (1.33%) for $100 million under the current buyback, with no shares repurchased in the latest quarter.Seeking Alpha • Mar 13
Penumbra Off And Running On Renewed Enthusiasm For Mechanical Thrombectomy
Summary Penumbra's shares have surged again on renewed confidence in mechanical thrombectomy growth and a competitor's acquisition, but the current valuation is high at over 7x 2025 revenue estimate. Penumbra's thrombectomy business grew significantly in Q4'24, with U.S. revenue up 27% and venous revenue up 40%, driven by ongoing market penetration and share gains. Future growth looks promising with new products like Thunderbolt in stroke thrombectomy and ongoing penetration of other mechanical thrombectomy markets, but Stryker's Inari remains a formidable rival. Despite strong growth prospects, Penumbra's current valuation already reflects these expectations, making it a less than ideal candidate for GARP-type investors. Read the full article on Seeking AlphaSeeking Alpha • Jan 07
Penumbra: Re-Rated For The Wrong Reasons
Summary Penumbra has shown significant operating leverage and profitability, with strong topline growth and a more than five-fold increase in revenue since its IPO in 2015. Despite a recent recovery in share price, growth has slowed, particularly due to challenges in China, leading to a cautious stance. Current valuation multiples have expanded, but growth expectations have softened, making the risk-reward proposition less attractive. I have sold out of my modest position due to higher expectations and slower growth, but Penumbra remains an interesting company to watch for future opportunities. Read the full article on Seeking Alpha
Nouveau récit • Aug 27
CAVT Technology Powers Thrombectomy Leader To Transformative Growth And Global Expansion
Introduction of CAVT technology positions Penumbra as a thrombectomy leader, driving revenue growth through innovation and market share gains.Seeking Alpha • Aug 20
Penumbra Grinding Through A Painful Growth Expectations Reset
Summary Penumbra's stock has sold off sharply over the last year as decelerating revenue growth has spooked growth investors out of this high-multiple stock. Q2 results included 14% revenue growth, a small beat versus the Street, and improved margins, but management reduced revenue guidance by $60M (around 5%). Penumbra isn't the only player seeing a slower VTE/thrombectomy market, as Inari's business has also slowed; it's unclear what is driving the slowdown, but temporary market saturation is plausible. Penumbra's core VTE markets are only about 20% penetrated, and there are compelling arguments for using thrombectomy in eligible patients instead of anticoagulants. Penumbra is a borderline call today; I can make a case for a share price of $225, but it may take a few more quarters for the business to reaccelerate. Read the full article on Seeking AlphaSeeking Alpha • May 30
Penumbra: Appeal Improves As Operating Leverage Continues
Summary Penumbra, a neurovascular player, has experienced solid topline growth over the past decade, now accompanied by operating leverage. Shares have fallen 20% from February levels, making them more appealing, but valuations are still demanding. The company's focus on removing clots and treating aneurysms has led to strong growth, as I am willing to dip my toes into the water on further dips. Read the full article on Seeking AlphaRendement pour les actionnaires
| PEN | US Medical Equipment | US Marché | |
|---|---|---|---|
| 7D | 0.4% | -0.4% | 0.1% |
| 1Y | 28.1% | -12.4% | 18.9% |
Rendement vs Industrie: PEN a dépassé le secteur US Medical Equipment qui a rapporté -12.4 % au cours de l'année écoulée.
Rendement vs marché: PEN a dépassé le marché US qui a rapporté 18.9 % au cours de l'année écoulée.
Volatilité des prix
| PEN volatility | |
|---|---|
| PEN Average Weekly Movement | 1.1% |
| Medical Equipment Industry Average Movement | 8.4% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.1% |
Cours de l'action stable: PEN n'a pas connu de volatilité de prix significative au cours des 3 derniers mois par rapport au marché US.
Volatilité au fil du temps: La volatilité hebdomadaire de PEN ( 1% ) est restée stable au cours de l'année écoulée.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 2004 | 4,700 | Adam Elsesser | www.penumbrainc.com |
Penumbra, Inc. et ses filiales conçoivent, développent, fabriquent et commercialisent des dispositifs médicaux aux États-Unis et dans le monde entier. Elle propose des produits de thrombectomie sous vide assistée par ordinateur, des produits de thrombectomie périphérique, notamment le système Indigo pour l'aspiration électrique des thrombus dans le corps, Lightning Flash, un système de thrombectomie mécanique, Lightning Bolt 7, un système de thrombectomie artérielle, et CAT RX. Elle fournit également des produits d'accès, notamment des cathéters de guidage et les cathéters d'administration distale Penumbra sous les marques Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25, MIDWAY et PX SLIM ; Le système Penumbra, un système intégré de thrombectomie mécanique comprenant des cathéters de reperfusion et des séparateurs, le dispositif de revascularisation 3D, des tubes d'aspiration, une pompe d'aspiration et d'autres composants et accessoires sous les marques Penumbra RED, SENDit, JET, ACE, BMX, Max, dispositif de revascularisation 3D et Penumbra ENGINE ; et des systèmes de coiling par embolisation neurologique comprenant le Penumbra Coil 400, pour le traitement des anévrismes et autres lésions complexes, des coils détachables pour les lésions neurovasculaires sous les marques Penumbra SMART COIL, SwiftSET, et Penumbra SwiftPAC Coil ; et les marques POD400 et PAC400.
Penumbra, Inc. Résumé des fondamentaux
| PEN statistiques fondamentales | |
|---|---|
| Capitalisation boursière | US$12.88b |
| Bénéfices(TTM) | US$160.59m |
| Recettes(TTM) | US$1.50b |
80.2x
Ratio P/E8.6x
Ratio P/SLe site PEN est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| PEN compte de résultat (TTM) | |
|---|---|
| Recettes | US$1.50b |
| Coût des recettes | US$483.98m |
| Marge brute | US$1.02b |
| Autres dépenses | US$860.31m |
| Les revenus | US$160.59m |
Derniers bénéfices déclarés
Jun 30, 2026
Prochaine date de publication des résultats
s/o
| Résultat par action (EPS) | 4.08 |
| Marge brute | 67.84% |
| Marge bénéficiaire nette | 10.67% |
| Ratio dettes/capitaux propres | 0% |
Quelles ont été les performances à long terme de PEN?
Voir les performances historiques et les comparaisonsAnalyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/08/17 12:35 |
| Cours de l'action en fin de journée | 2026/08/17 00:00 |
| Les revenus | 2026/06/30 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github ; nous proposons également des guides sur la façon d’utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Penumbra, Inc. est couverte par 29 analystes. 13 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| David Rescott | Baird |
| null null | Baird |
| Joanne Wuensch | BMO Capital Markets Equity Research |